PDF-LeadingEdgePrimaryAdaptiveandAcquiredResistancetoCancerImmunotherapy
February920172017ElsevierInc
10yearsormoreinasubsetofapproximately21ofpatientsSchadendorfetal2015In2015ipilimumabwasalsoapprovedbytheFDAasadjuvanttherapyforlocallyadvancedmelanomaDuetoenhanc
Download Presentation
"LeadingEdgePrimaryAdaptiveandAcquiredResistancetoCancerImmun " is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
Transcript not available.